Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Eisai To Build New Parenteral Facility | Contract Pharma

What are you searching for?

Sign in
Breaking News

Eisai To Build New Parenteral Facility

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Eisai, Inc. has plans for a new pharmaceutical production and formulation R&D facility for parenteral oncology treatments. Eisai has a number of drugs in development for patients with cancer.

“Oncology is one of Eisai’s long-standing therapeutic areas of focus, supporting our human health care mission to increase benefits to patients and their families and satisfy unmet medical needs,” said Lonnel Coats, president and chief operating officer, Eisai “Our plans for the new facility in RTP demonstrate Eisai’s global commitment to oncology and patients around the world.”

The new $90 million, 65,000-sq.-ft. facility will encompass aseptic processing suites, laboratories and other support functions. A separate $15 million central utilities building is also planned to supply power, steam, chilled water and compressed air to the existing operations and the new parenteral facility. Groundbreaking is expected in the fall and completion is anticipated in three years with operations beginning in 2009. The new facilities will lead to 59 new jobs during the next three years and a total of 84 new jobs during the next five years.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics